methenolone

The clinical adverse events that occurred in 2% of patients intravenously received ganciclovir, regardless of causal relationship to medication and severity: the blood methenolone system and lymphatic system:neutropenia, anemia, thrombocytopenia, leukopenia, lymphadenopathy, by of the digestive system: diarrhea, abdominal pain, dysphagia, esophageal candidiasis, the body as a whole: fever, candidiasis, an infection at the injection site, sepsis, secondary sepsis, anorexia, mycobacteriosis (mycobacterium avium), pain of various localization, chest pain, bacteremia ; from the central and peripheral nervous system: gipoesteziya, anxiety; from the side of the skin and its appendages: pruritus, from respiratory: cough, Pneumocystis pneumonia, cough, congestion in the sinuses; laboratory parameters: increase in activity of alkaline phosphatase in the blood, increased creatinine in the blood, neutropenia, anemia, thrombocytopenia, increased creatinine, from the musculoskeletal system: arthralgia.

Patients after transplantation

Clinical adverse events that occurred of patients intravenously received ganciclovir for the treatment or prevention of symptomatic methenolone disease after bone marrow transplantation, regardless of causal relationship to medication and severity: the part of hematopoiesis: pancytopenia, leukopenia, the body as a whole : mucous membranes, fever, shivering, sepsis, anorexia, swelling of the face, from the side of the digestive system: diarrhea, dyspepsia, laboratory parameters: increase of serum creatinine, liver transaminases, hypomagnesemia, hypocalcemia, hypokalemia, in the nervous system:headache, tremor, confusion, on the part of the skin and its appendages: exfoliative dermatitis, from respiratory: rhinitis, dyspnea, from the cardiovascular system: tachycardia, hypotension, on the part of the urinary tract: hematuria; senses: eye hemorrhage ; musculoskeletal system: myalgia.

 

Clinical adverse events that occurred of patients receiving intravenous ganciclovir after a heart transplant, regardless of causal relationship to drug or severity: Body as a Whole: infection (18%).Metabolic and Nutritional: edema (9%). Central and peripheral nervous system: headache (18%), confusion (5%), peripheral neuropathy (7%). respiratory: pleural methenolone effusion (5%). Cardiovascular system:hypertension (20%). Genitourinary tract: renal impairment (14%), renal failure (12%).

Due to the high bioavailability of intravenous ganciclovir can not be excluded that the intravenous administration of the drug may experience the same adverse events as well as in studies with oral ganciclovir.